Researchers say they are one step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.
The news comes amid the worst ever outbreak of the hemorrhagic fever, which has killed 5,500 people so far, mostly in West Africa.
Pharmaceutical companies and health agencies scramble to fast-track experimental drugs and vaccines that could help.
In the first phase of testing, all 20 healthy adults injected with a higher or lower dose of the vaccine developed antibodies needed to fight Ebola, said the National Institutes of Health (NIH), which conducted the study.
Results were published Wednesday in the New England Journal of Medicine.
"The unprecedented scale of the current Ebola outbreak in West Africa has intensified efforts to develop safe and effective vaccines," said Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, which is developing the vaccine alongside GlaxoSmithKline.
The vaccines under development "may play a role in bringing this epidemic to an end and undoubtedly will be critically important in preventing future large outbreaks," he noted.
"Based on these positive results from the first human trial of this candidate vaccine, we are continuing our accelerated plan for larger trials to determine if the vaccine is efficacious in preventing Ebola infection," he added.
But the NIAID/GSK vaccine is still a long way from being ready for use in the field.
The NIAID is "in active discussions with Liberian officials and other partners about next-stage vaccine testing in West Africa" for efficacy and safety, the NIH said, but no announcement on larger-scale trials was expected before early next year.
There is no licensed treatment or vaccine against the Ebola virus, which is transmitted through bodily fluids and has been fatal in an estimated 70 percent of cases in the current outbreak.
Antibodies within four weeks
The volunteers were injected starting in September, and each showed a positive result for Ebola antibodies in blood tests within four weeks.
The 10 volunteers in the higher-dose group developed higher antibody levels, the NIH said.
In addition, two of the lower-dose group and seven of the higher-dose group developed a kind of immune cell called CD8 T cells, which are an important part of the body's response against disease.
"We know from previous studies in non-human primates that CD8 T cells played a crucial role in protecting animals" who got the vaccine and then were exposed to Ebola, said researcher Julie Ledgerwood, the trial’s principal investigator.
None of the volunteers experienced serious side effects within the study period, though two had a brief, mild fever within the 24 hours after the injection.
The vaccine uses a modified chimpanzee cold virus to deliver segments of genetic material from the Ebola virus.
The genetic material cannot spread in the body like the virus does, but can still prompt the antibody response.
The version tested at NIH contains material from two species of Ebola -- the Zaire species, responsible for the outbreak in West Africa, and another called Sudan Ebola.
"This work is encouraging and another significant contribution to efforts to tackle the Ebola crisis," said Dr Jeremy Farrar, Director of the Wellcome Trust.
The White House also congratulated the vaccine researchers.
"We congratulate Drs Francis Collins and Tony Fauci and their teams at the National Institutes of Health on the first published results from Phase 1 clinical trials of a promising Ebola vaccine candidate," a White House statement said, adding that President Barack Obama would visit the NIH next week.
A second version of the vaccine, aimed at blocking just Zaire Ebola, also began human testing in October, at the University of Maryland.
Another experimental vaccine that has shown promising results in primates is the Canadian VSV-EBOV, licensed by US firm NewLink Genetics. It is also in early stages of human testing.
AFP
Thu Nov 27 2014
A nurse draws blood from British volunteer Ruth Atkins before getting injected with the Ebola vaccine at the Oxford Vaccine Group Centre on Sept 17, 2014. AFP PHOTO/POOL/STEVE PARSONS
Shooting in Washington state leaves 5 dead; 15-year-old boy is in custody
The boy taken into custody was booked at the King County juvenile detention facility.
Malaysia to launch ASEAN Chairmanship 2025 logo and theme
Foreign Minister Datuk Seri Mohamad Hasan will launch the logo and theme during a ceremony at the Wisma Putra, in Putrajaya.
Ukraine blasts UN's Guterres over invitation to BRICS summit in Russia
The UN Secretary General declined Ukraine's invitation to the first Global Peace Summit in Switzerland, the ministry said.
Hospitals under fire as Israeli forces deepen operations in northern Gaza
Troops rounded up men and ordered women to leave the Jabalia historic refugee camp, residents and medics said.
Taiwan says live fire China drills may be part of a 'deterrence' effect
Taiwan's defence ministry said those exercises were part of routine Chinese training and it was keeping a close watch.
Bursa Malaysia's early gains erode as investors lock in profits
The benchmark index had initially opened 1.78 points firmer at 1,647.46.
Brazil's Lula says head injury 'serious,' with update from doctors in coming days
The president's injury forced him to cancel a trip to Russia for a summit of the BRICS group of major emerging markets being held in Kazan.
Blinken heads to Israel to revive Gaza ceasefire talks after Sinwar death
Blinken will focus discussions on how to end the war, plans for the enclave after the fighting ends and how to improve humanitarian assistance.
Facebook owner Meta restarts facial recognition tech in 'celeb-bait' crackdown
Meta said it will enroll about 50,000 public figures in a trial which involves automatically comparing their Facebook profile photos with images used in suspected scam advertisements.
BHP trying to avoid responsibility over Brazilian dam collapse, UK court told
More than 600,000 Brazilians, 46 local governments and around 2,000 businesses are suing BHP over the 2015 collapse of the Mariana dam in southeastern Brazil.
Minimum wage not benchmark for all employees' starting salaries - Sim
Steven Sim says the increase in the minimum wage is intended as a basic wage for workers with lower academic qualifications and skills.
Climate and China weigh on how the US views Pacific relations
Pacific leaders keep their preference for US President quiet, yet viewing relations only through the lens of China does nobody a service.
Gulen, the powerful cleric accused of orchestrating a Turkish coup, dies
Gulen was a one-time ally of Erdogan but they fell out spectacularly, and Erdogan held him responsible for the 2016 attempted coup.
[COLUMNIST] The reality of earthquakes in Malaysia: A threat we can’t ignore
The government needs to prepare the public to deal with such disasters in any way possible.
'PROTEGE-Veteran' provides job assurance for retirees
This is an aggressive step by the government to protect the welfare of retirees, said Dr Mohd Hasril Amiruddin.
US says THAAD anti-missile system is 'in place' in Israel
THAAD is a critical part of the US military's layered air defense systems and adds to Israel's already formidable anti-missile defenses.
IMAN Research calls for strengthening human security in 2025 Budget
IMAN Research identifies key areas for enhancement within the Malaysian government's Third MADANI Budget 2025.
Zambry assures academics of freedom of speech
Zambry says he is committed to preventing any actions that could infringe upon the rights and freedoms of academics across universities.
Media licensing framework development involves multiple consultations - Teo
Teo Nie Ching says the views of stakeholders have been considered through several engagement sessions and ongoing consultations.
ANALYSIS - World lags on 2030 nature goals headed into UN COP16 talks
A top concern for countries and companies is how to pay for conservation, with the COP16 talks aiming to develop new initiatives.